Carolyn Britten, MD

Bio:

Carolyn Britten, M.D., Vice President Clinical Development Sold Tumors, oversees a portfolio of assets including ADCs, novel IO, and degraders within the Lung Cancer Franchise at BeOne Medicines. Prior to joining BeOne, Carolyn was at Amgen, where she held positions of increasing responsibility, culminating as Vice President and Therapeutic Area Head for Oncology Early Development.  Carolyn pivoted to industry after a career in academic medicine, first leading the Oncology Phase 1 Program embedded within the Signal Transduction Lab at the University of California at Los Angeles, and later joining the Medical University of South Carolina where she served as the Hematology/Oncology Division Chief.  Over the course of her academic career, Carolyn held peer reviewed funding in breast cancer, gastrointestinal malignancies, and infrastructure to support underserved patient populations. Carolyn is a graduate of the University of Toronto, a Fellow of the Royal College of Physicians and Surgeons of Canada, and she is board-certified­ in Medical Oncology by the American Board of Internal Medicine.